View in EDS

Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine.

Saved in:
Bibliographic Details
Title: Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine.
Authors: Aboshi M; VLP Therapeutics Japan, Inc., 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan., Matsuda K; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA., Kawakami D; VLP Therapeutics Japan, Inc., 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan., Kono K; VLP Therapeutics Japan, Inc., 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan., Kazami Y; VLP Therapeutics Japan, Inc., 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan., Sekida T; VLP Therapeutics Japan, Inc., 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan., Komori M; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA., Morey AL; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA., Suga S; National Hospital Organization, Mie National Hospital, Tsu, Mie 514-0125, Japan., Smith JF; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA., Fukuhara T; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido 060-0815, Japan.; Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan., Iwatani Y; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi 460-0001, Japan.; Division of Basic Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan., Yamamoto T; Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka 567-0085, Japan., Sato N; VLP Therapeutics Japan, Inc., 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan., Akahata W; VLP Therapeutics Japan, Inc., 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan.
Source: IScience [iScience] 2024 Jan 22; Vol. 27 (2), pp. 108964. Date of Electronic Publication: 2024 Jan 22 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101724038 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-0042 (Electronic) Linking ISSN: 25890042 NLM ISO Abbreviation: iScience Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38352232
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Aboshi+M%22">Aboshi M</searchLink>; VLP Therapeutics Japan, Inc., 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan.<br /><searchLink fieldCode="AU" term="%22Matsuda+K%22">Matsuda K</searchLink>; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA.<br /><searchLink fieldCode="AU" term="%22Kawakami+D%22">Kawakami D</searchLink>; VLP Therapeutics Japan, Inc., 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan.<br /><searchLink fieldCode="AU" term="%22Kono+K%22">Kono K</searchLink>; VLP Therapeutics Japan, Inc., 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan.<br /><searchLink fieldCode="AU" term="%22Kazami+Y%22">Kazami Y</searchLink>; VLP Therapeutics Japan, Inc., 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan.<br /><searchLink fieldCode="AU" term="%22Sekida+T%22">Sekida T</searchLink>; VLP Therapeutics Japan, Inc., 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan.<br /><searchLink fieldCode="AU" term="%22Komori+M%22">Komori M</searchLink>; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA.<br /><searchLink fieldCode="AU" term="%22Morey+AL%22">Morey AL</searchLink>; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA.<br /><searchLink fieldCode="AU" term="%22Suga+S%22">Suga S</searchLink>; National Hospital Organization, Mie National Hospital, Tsu, Mie 514-0125, Japan.<br /><searchLink fieldCode="AU" term="%22Smith+JF%22">Smith JF</searchLink>; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA.<br /><searchLink fieldCode="AU" term="%22Fukuhara+T%22">Fukuhara T</searchLink>; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido 060-0815, Japan.; Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan.<br /><searchLink fieldCode="AU" term="%22Iwatani+Y%22">Iwatani Y</searchLink>; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi 460-0001, Japan.; Division of Basic Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan.<br /><searchLink fieldCode="AU" term="%22Yamamoto+T%22">Yamamoto T</searchLink>; Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka 567-0085, Japan.<br /><searchLink fieldCode="AU" term="%22Sato+N%22">Sato N</searchLink>; VLP Therapeutics Japan, Inc., 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan.<br /><searchLink fieldCode="AU" term="%22Akahata+W%22">Akahata W</searchLink>; VLP Therapeutics Japan, Inc., 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101724038%22">IScience</searchLink> [iScience] 2024 Jan 22; Vol. 27 (2), pp. 108964. <i>Date of Electronic Publication: </i>2024 Jan 22 (<i>Print Publication: </i>2024).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Cell+Press%22">Cell Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101724038 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2589-0042 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225890042%22">25890042 </searchLink><i>NLM ISO Abbreviation: </i>iScience <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38352232
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.isci.2024.108964
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 108964
    Titles:
      – TitleFull: Safety and immunogenicity of VLPCOV-02, a SARS-CoV-2 self-amplifying RNA vaccine with a modified base, 5-methylcytosine.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Aboshi M
      – PersonEntity:
          Name:
            NameFull: Matsuda K
      – PersonEntity:
          Name:
            NameFull: Kawakami D
      – PersonEntity:
          Name:
            NameFull: Kono K
      – PersonEntity:
          Name:
            NameFull: Kazami Y
      – PersonEntity:
          Name:
            NameFull: Sekida T
      – PersonEntity:
          Name:
            NameFull: Komori M
      – PersonEntity:
          Name:
            NameFull: Morey AL
      – PersonEntity:
          Name:
            NameFull: Suga S
      – PersonEntity:
          Name:
            NameFull: Smith JF
      – PersonEntity:
          Name:
            NameFull: Fukuhara T
      – PersonEntity:
          Name:
            NameFull: Iwatani Y
      – PersonEntity:
          Name:
            NameFull: Yamamoto T
      – PersonEntity:
          Name:
            NameFull: Sato N
      – PersonEntity:
          Name:
            NameFull: Akahata W
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 22
              M: 01
              Text: 2024 Jan 22
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 2589-0042
          Numbering:
            – Type: volume
              Value: 27
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: IScience
              Type: main
ResultId 1